* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Drug Dosage and Clinical Responses
Discovery and development of beta-blockers wikipedia , lookup
Discovery and development of angiotensin receptor blockers wikipedia , lookup
Compounding wikipedia , lookup
Orphan drug wikipedia , lookup
Cannabinoid receptor antagonist wikipedia , lookup
NK1 receptor antagonist wikipedia , lookup
Nicotinic agonist wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Drug design wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Theralizumab wikipedia , lookup
Prescription costs wikipedia , lookup
Drug discovery wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Pharmacognosy wikipedia , lookup
Drug interaction wikipedia , lookup
Neuropharmacology wikipedia , lookup
Drug Dosage and Clinical Responses September 12, 2007 Frank F. Vincenzi Learning Objectives • • • • • • • • Antagonism Potency Clinical efficacy Slope of D-R curve Quantal response ED50, LD50, TI Synergism Summation • • • • • • • Tolerance Tachyphylaxis Idiosyncrasy Drug allergy Therapeutic/side effects Adverse effects Toxicology Factors Modifying Drug Responses (The Big Three) • Drug (pharmacodynamics) • Dose (pharmaco/dynamics/kinetics) • Route of Administration (pharmacokinetics) Factors Modifying Drug Responses (cont): The ‘big many’ • • • • • • Tolerance Dependence Age Weight Sex Pharmacogenetics • • • • • • • Set Setting Dosing errors Non-compliance Drug interactions Disease! Attitude! Antagonism • Combined effect of the two drugs is less than the sum of their individual effects – Types of antagonism Pharmacological (agonist/antagonist) (pure antagonist + full agonist) (i.e., 0 + 6 = 1) (partial agonist + full agonist) (i.e., 2 + 6 = 4) – Chemical – direct chemical interaction (e.g., chelation) – Physiological – Two drugs produce opposite effects on the same system (epinephrine in the treatment of histamine-induced bronchospasm) Synergism • The combined effect of two drugs is greater than the sum of their individual effects i.e., 1 + 1 = 6 or 0 + 4 = 10 (often called ‘potentiation’) Potency and Clinical Efficacy/Efficiency • Potency refers to the amount of drug necessary to produce a certain effect. A drug which produces a certain effect at 5 mg dosage is ten times more potent than a drug which produces the same effect at 50 mg dosage. • Clinical efficacy (or simply efficacy) refers to the maximal clinical response that can be obtained by a particular drug (morphine is more clinically efficacious than aspirin as an analgesic) * • Clinical efficiency is the bottom line of how well an intervention actually works (includes compliance) Healthy Volunteers (Medical Students?) and Intravenous Sodium Amytal (n = 55) Adapted from Clark’s Applied Pharmacology Clinical Responses to Drugs are Often Expressed Quantally: Quantal Dose-Response Curve Medical Students (?) and Intravenous Sodium Amytal (n = 55) Adapted from Clark’s Applied Pharmacology Population Quantal Dose-Response Curve • Position is a reflection of drug potency. Drugs that produce a certain effect at a low dose are more potent than drugs that produce the same effect at a higher dose. • Slope is a reflection of the dispersion of sensitivity to the drug among members of the population. The steeper the slope the more homogeneous the population. Therapeutic Effect of Prazosin: Lowering of Blood Pressure by 10 mm Hg Isoniazid levels in patients subjected to a standard dose - an example of pharmacokinetically determined tolerance/sensitivity Therapeutic and Side Effects of Drugs • Therapeutic effect: the desired clinical effect • Side effects: any other clinical effects (may include neutral or adverse events) Frequency distribution and cumulative % responses of a population to a drug Calculation of Median Therapeutic Index Different therapeutic indices of a given drug with more than one therapeutic effect Several measures of relative drug safety • Median Therapeutic Index, TI = LD50/ED50 • ‘Conventional Index’ = LD1/ED1 • ‘Standard Safety Margin’ = ([LD1/ED99 - 1])*100 • ‘Standard Safety Margin’ = ([LD0.1/ED99.9 - 1])*100 Examples of relative toxicities of some psychotropic drugs Changes in therapeutic index of a chronically administered barbiturate: dispositional and cellular tolerance Tolerance • A condition produced by repeated or continued exposure to a drug that produces decreased responses to that drug when given at a certain dosage - or that increased doses are needed to maintain a certain level of response. • (Cross tolerance refers to the same phenomenon involving chemically or mechanistically related drugs). Subsets of Tolerance • Tachyphylaxis (e.g., indirectly acting sympathomimetic amines) • Tolerance – Dispositional – Cellular – Behavioral Receptor Desensitization: One Potential Mechanism of Cellular Tolerance Reversible decrease in the sensitivity to agonist(s) of responses mediated by a particular receptor or receptor signaling pathway. Example: agonist binds to the beta-receptor then betaadrenoceptor kinase (ARK), phosphorylates the betaadrenoceptor protein - this promotes the binding of beta-arrestin and decreases interaction of the receptor with the G protein, Gs. Removal of agonist allows phosphatases to ‘reset’ the receptor. Down Regulation of Receptors: Another potential mechanism of cellular tolerance Agonist-induced decrease in the number of available receptors of a particular type. This decreases the sensitivity of the system to responses mediated by the receptor in question. Example: altered receptor turnover that results in fewer available receptors for activation in chronic opiate usage, etc. (basis of tissue tolerance). Up Regulation of Receptors Antagonist- or ‘dis-use’-induced increase in the number of available receptors of a particular type. This increases the sensitivity of the system to responses mediated by the receptor in question (increased number of spare receptors). Example: ‘denervation supersensitivity’ The ‘Therapeutic Window’ Ratio of the maximum concentration that is non-toxic in most of the population (various toxicities) to the minimum concentration that is effective in most of the population (e.g., theophylline 10 - 20 µg/ml) (avg.TD/ED in the ninth edition of Goodman & Gilman’s = 2.79 ± 3.2 (0.23 - 15) THEREFORE: A decimal point is a potentially lethal weapon!! You MUST know pg, ng, µg, mg, g, kg, etc. Practical limitations on clinical dosing: Therapeutic and side effects of digitoxin Adverse Drug Reactions • • • • • Overdosage (includes interactions, genetics, suicide) Side effects (most are predictable) Secondary effects (e.g., overgrowth) Idiosyncrasy (unpredictable, by definition) Drug allergy (also called hypersensitivity) Drugs Commonly Associated with Adverse Reactions • In hospitalized patients: • Leading to hospitalization: • • • • • • • • • digoxin heparin hydrochlorothiazide spironolactone aspirin digoxin hydrochlorothiazide prednisone warfarin Adverse Drug Reactions Associated with Multiple Drugs Mortality Associated with Multiple Drugs Dependence • “A cluster of cognitive, behavioral, and physiological symptoms indicating that the individual continues use of the substance despite significant substance-related problems.” (DSM-IV) • Psychological - withdrawal mainly psychological • Physical - the hallmark of physical dependence is ‘physical’ withdrawal. May have cross dependence. Substance Abuse • “…a maladaptive pattern of substance use manifested by recurrent and significant adverse consequences related to the repeated use of substances.” (DSM IV) (Note: The criteria do not include tolerance, withdrawal or a pattern of compulsive use. Also note, DSM IV never uses the term ‘addiction’) • Curiously: The category of substance abuse does not apply to caffeine and nicotine - at least according to DSM IV. ADDICTION: A more ‘official’ view “Uncontrollable, compulsive drug seeking and use, even in the face of negative health and social consequences” – Alan L. Leshner, Ph.D., Director of NIDA in: The Brain: Understanding Neurobiology Through the Study of Addiction